- Featured Product
- KD/KO Validated
CEA Polyclonal Antibody for IHC, ELISA
Cat no : 10421-1-AP
Carcinoembryonic antigen, CD66e, CEA, CEACAM5, Meconium antigen 100
|Positive IHC detected in||human colon cancer tissue, human stomach cancer tissue, human appendicitis tissue, human lung cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
10421-1-AP targets CEA in WB, IHC, chIP, ELISA applications and shows reactivity with human samples.
|Host / Isotype||Rabbit / IgG|
|Immunogen||CEA fusion protein Ag0672|
|Full Name||carcinoembryonic antigen-related cell adhesion molecule 5|
|Calculated molecular weight||77 kDa|
|Observed molecular weight|
|GenBank accession number||BC034671|
|Gene ID (NCBI)||1048|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.1% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Carcinoembryonic antigen (CEA), also known as CEACAM5 or CD66e, is a cell surface glycoprotein belonging to the immunoglobulin superfamily, mainly serving as a cell adhesion molecule mediating intercellular contact by both homophilic and heterophilic binding (PMID: 21731662). CEA inhibits anoikis and plays a role in tumorigenesis and metastasis. CEA has been found to be overexpressed in a wide variety of human cancers, including colon, breast, and lung (PMID: 17167768). CEA is a tumor marker and is routinely exploited for diagnosis.
Lentivirus-mediated RASSF1A expression suppresses aggressive phenotypes of gastric cancer cells in vitro and in vivo.
Molecular signature of interleukin-22 in colon carcinoma cells and organoid models.
Discovery of Aquaporin-1 and Aquaporin-4 Expression in an Intramedullary Spinal Cord Ependymal Cyst: Case Report.
Int J Biol Sci
FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1α/CEACAM5 functional axis.